Title

Selective thromboxane inhibition: a new approach to antiplatelet therapy

UMMS Affiliation

Department of Neurology; Department of Medicine, Division of Cardiovascular Medicine

Publication Date

1984-09-01

Document Type

Article

Subjects

Animals; Cerebrovascular Disorders; Imidazoles; Male; Platelet Aggregation; Swine; Thromboxane B2; Thromboxanes

Disciplines

Medicinal and Pharmaceutical Chemistry | Neurology | Pharmacy and Pharmaceutical Sciences

Abstract

Antiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.

Source

Stroke. 1984 Sep-Oct;15(5):813-6.

Journal/Book/Conference Title

Stroke; a journal of cerebral circulation

Related Resources

Link to article in PubMed

PubMed ID

6474531

Share

COinS